SCHEMBL7040375

SCHEMBL7040375

CC(C)(C)c1ccc(Br)cc1Oc1ccccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.41
MAOA P21397 1/20 0.39
P2RY1 P47900 3/20 0.38
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
MRGPRX1 Q96LB2 1/20 0.36
CYP3A4 P08684 1/20 0.36
ESRRA P11474 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
AR P10275 2/20 0.35
KDM1A O60341 2/20 0.35
HTR1A P08908 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
NR1I2 O75469 1/20 0.34
CYP2C8 P10632 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044342 0.81 AR (0.40) IDO1PTGDR2ARSLC6A2SLC6A4
SCHEMBL7044485 0.79 IDO1 (0.38) IDO1P2RY1MRGPRX1CYP3A4ESRRA
SCHEMBL30513618 0.79 IDO1 (0.39) IDO1P2RY1NR1I2CYP2C8ALDH1A1
SCHEMBL30513619 0.79 IDO1 (0.39) IDO1P2RY1NR1I2CYP2C8ALDH1A1
SCHEMBL7041287 0.78 AR (0.43) IDO1MAOAPTGDR2ARSLC6A2
SCHEMBL7041843 0.77 RXRA (0.51) IDO1TDP1
SCHEMBL16344881 0.77 IDO1 (0.41) IDO1MAOAP2RY1CYP3A4PTGDR2
SCHEMBL1685381 0.76 LTA4H (0.46) IDO1P2RY1THRATHRBMRGPRX1
SCHEMBL127278 0.76 ALDH1A1 (0.48) P2RY1ALDH1A1TDP1
SCHEMBL30500977 0.76 ALDH1A1 (0.48) P2RY1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660755-B2 Controlling cell proliferation agent; skin disorders; antiinflamamtory agents ALLERGAN, INC. 2003-12-09 US disclosed
US-20030109687-A1 Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity ALLERGAN, INC. 2003-06-12 US disclosed
US-6455701-B1 SUCH AS 4-((4'-TERT-BUTYL-3'-(4?-TRIFLUOROMETHYL)PHENOXY) PHENYLETHYNYL)BENZOIC ACID; SIDE EFFECT REDUCTION ALLERGAN, INC. 2002-09-24 US disclosed
US-6187950-B1 A REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES ALLERGAN, INC. 2001-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109687-A1 Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity RXRB, RXRA, RXRG IDO1 3174/4885MAOA 1071/4885P2RY1 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.